Overview

The Recovery of Cardiovascular Patients With Depression

Status:
Recruiting

Trial end date:
2021-11-01

Target enrollment:
0

Participant gender:
All

Summary

Cardiovascular disease increases the risk of depression and vice versa. Many cardiovascular patients are subjected to percutaneous coronary intervention (PCI). Potential biomarkers for the development, the course and the recovery of both diseases are in the focus of interest of many studies. One of the biomarkers that stands out is brain derived neurotrophic factor (BDFN). BDNF plays a significant role in regulating vascular growth and repair but also stimulates the survival, differentiation, and conservation of neurons. The aim of the study is to detect the depression in patients undergoing PCI and to determine the impact of psychiatric treatment on the functional recovery and on the changes of BDNF.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Klinički Bolnički Centar Zagreb

Treatments:

Citalopram
Dexetimide
Sertraline

Criteria

Inclusion Criteria:

- patients on day of percutaneous coronary intervention due to angina pectoris or
myocardial infarction

- without antidepressant drugs or major tranquilizers more than one year

Exclusion Criteria:

- symptoms of myocardial infarction lasting more than 12 hours

- left ventricle ejection function (LVEF) less than 40%

- earlier presence of cardiomyopathy

- acute infection